Biotech Values

[DewDiligence]

AGN, EDIT announce mutual opt-ins on EDIT-101:

https://www.prnewswire.com/news-releases/allergan-and-editas-medicine-announce-exercise-of-options-to-jointly-develop-crispr-genome-editing-experimental-medicine-edit-101-300692493.html

…[Allergan] has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.

Under the terms of the option agreement signed in March 2017 [#msg-129491806], Allergan has paid Editas Medicine a fee of $15 million in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25 million from Allergan upon acceptance of an investigational new drug (IND) application for EDIT-101 by the Food & Drug Administration (FDA).